Själander S, et al. - Nationwide retrospective cohort study based on Swedish quality registries was conducted to examine efficacy and safety of apixaban, dabigatran or rivaroxaban compared with warfarin in clinical practice. Between 2013-01-01 and 2015-12-31, atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin were involved. No difference was found between apixaban, dabigatran, or rivaroxaban compared to high TTR warfarin treatment regarding stroke prevention. Data reported that fewer bleeding events were seen for apixaban and dabigatran, but not for rivaroxaban.